UbiVac is a company that offers a pipeline of groundbreaking immunotherapies in preclinical and clinical stage trials. Since 2005 the company has been engaged in the research, development and testing of therapeutic immunotherapy strategies to combat cancer and infectious diseases.
UbiVac’s lead product, DPV-001 (DRibble) is a first in class DC-targeted complex vaccine/combination immunotherapy that is now in Phase II clinical trials for lung cancer. A pilot study of the vaccine is open for patients with prostate cancer, and a Phase II trial for breast cancer will open third quarter of 2015. Further Phase 1/II trials for this therapy will open later this year for Mesothelioma. Randomized, multi-center Phase II trials for DPV-001, combined with anti PD-1 are planned for the fourth quarter of 2015. Phase I/II clinical trials for advanced head and neck squamous cell cancer will open in 2016.
UbiVac’s technology fills a gap in the oncology pipeline of every major pharmaceutical company.
Immunotherapy is hailed as a treatment of choice for the future. Generally this therapy has fewer side effects than traditional therapies, and offers the potential for a cure. Immunotherapy uses a patient’s immune system to fight disease.